167 related articles for article (PubMed ID: 38496757)
21. Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors.
Nastały P; Honecker F; Pantel K; Riethdorf S
Methods Mol Biol; 2021; 2195():245-261. PubMed ID: 32852768
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of plasma miR-371a-3p in germ cell tumors.
Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ
J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014.
Adra N; Althouse SK; Liu H; Brames MJ; Hanna NH; Einhorn LH; Albany C
Ann Oncol; 2016 May; 27(5):875-9. PubMed ID: 26861605
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
25. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
26. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer.
Allione A; Pardini B; Viberti C; Oderda M; Allasia M; Gontero P; Vineis P; Sacerdote C; Matullo G
Urol Oncol; 2018 May; 36(5):241.e15-241.e23. PubMed ID: 29426697
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
29. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
Feldman DR; Sheinfeld J; Bajorin DF; Fischer P; Turkula S; Ishill N; Patil S; Bains M; Reich LM; Bosl GJ; Motzer RJ
J Clin Oncol; 2010 Apr; 28(10):1706-13. PubMed ID: 20194867
[TBL] [Abstract][Full Text] [Related]
30. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells.
Kopjar N; Milas I; Garaj-Vrhovac V; Gamulin M
Clin Exp Med; 2006 Dec; 6(4):177-90. PubMed ID: 17191110
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
33. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C; Kollmannsberger C; Meisner C; Harstrick A; Beyer J; Metzner B; Hartmann JT; Schmoll HJ; Einhorn L; Kanz L; Nichols C
J Clin Oncol; 1999 Nov; 17(11):3450-6. PubMed ID: 10550141
[TBL] [Abstract][Full Text] [Related]
34. Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort.
Wessalowski R; Blohm M; Calaminus G; Engert J; Harms D; Krause I; Kruck H; Grüttner HP; Pape H; Göbel U
Klin Padiatr; 1997; 209(4):250-6. PubMed ID: 9293458
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
; Lorch A; Beyer J; Bascoul-Mollevi C; Kramar A; Einhorn LH; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin KA; Lotz JP; Germa Lluch JR; Powles T; Kollmannsberger CK
J Clin Oncol; 2010 Nov; 28(33):4906-11. PubMed ID: 20956623
[TBL] [Abstract][Full Text] [Related]
36. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.
Fankhauser CD; Gerke TA; Roth L; Sander S; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Beyer J; Hermanns T
J Cancer Res Clin Oncol; 2019 Mar; 145(3):781-785. PubMed ID: 30637464
[TBL] [Abstract][Full Text] [Related]
37. Prognostic role of plasma vitamin D and its association with disease characteristics in germ cell tumours.
Lesko P; Vlkova B; Kalavska K; De Angelis V; Novotna V; Obertova J; Orszaghova Z; Palacka P; Rejlekova K; Sycova-Mila Z; Kollarik B; Aziri R; Pindak D; Mardiak J; Chovanec M; Celec P; Mego M
Front Oncol; 2023; 13():1149432. PubMed ID: 37114140
[TBL] [Abstract][Full Text] [Related]
38. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ
J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042
[TBL] [Abstract][Full Text] [Related]
39. [High dose chemotherapy with autologous stem-cell support in germ cell tumors: The Instituto Português de Oncologia de Lisboa Francisco Gentil Series].
Brito M; Sanchez P; Velho S; Miranda N; Leal da Costa F; Ferreira I; Teixeira G; Guimarães A; Abecasis M; Passos Coelho JL
Acta Med Port; 2011; 24(4):533-44. PubMed ID: 22521011
[TBL] [Abstract][Full Text] [Related]
40. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
